UBS Group AG Buys 56,255 Shares of Theravance Biopharma, Inc. $TBPH

UBS Group AG increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 10.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 570,425 shares of the biopharmaceutical company’s stock after acquiring an additional 56,255 shares during the quarter. UBS Group AG’s holdings in Theravance Biopharma were worth $10,673,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of TBPH. AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma during the 1st quarter worth about $101,000. Jane Street Group LLC raised its stake in Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning acquired a new stake in Theravance Biopharma in the 2nd quarter worth about $139,000. American Century Companies Inc. raised its stake in Theravance Biopharma by 6.8% in the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Theravance Biopharma by 12.4% in the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 2,789 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on TBPH. HC Wainwright lifted their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. B. Riley Financial lifted their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Finally, BTIG Research reiterated a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research note on Friday, March 20th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Theravance Biopharma has a consensus rating of “Moderate Buy” and an average price target of $21.83.

Theravance Biopharma Stock Down 1.8%

Shares of Theravance Biopharma stock opened at $16.22 on Friday. Theravance Biopharma, Inc. has a twelve month low of $9.04 and a twelve month high of $21.03. The company has a 50-day simple moving average of $15.74 and a two-hundred day simple moving average of $17.45. The stock has a market capitalization of $836.14 million, a price-to-earnings ratio of 7.37 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, sell-side analysts anticipate that Theravance Biopharma, Inc. will post 0.95 earnings per share for the current fiscal year.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.65% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.